Amgen (AMGN) 160.18 $AMGN
Amgen Humira Biosimilar Briefing Documents Look Good
Arpita Dutt - Zacks Investment Research - Mon Jul 11, 7:04AM CDT
An FDA advisory panel will be meeting tomorrow to review Amgen Inc.'s (AMGN) ABP 501, a biosimilar version of AbbVie's Humira.
INVA: 11.77 (+0.13), FCSC: 1.18 (-0.02), AMGN: 160.18 (-0.92), ABBV: 64.35 (+0.19)
Zacks.com featured highlights: Wal-Mart Stores, Home Depot, Amgen, United Parcel Service and Intel
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:30AM CDT
Zacks.com featured highlights: Wal-Mart Stores, Home Depot, Amgen, United Parcel Service and Intel
HD: 135.15 (+0.81), AMGN: 160.18 (-0.92), WMT: 74.06 (+0.22), INTC: 34.38 (+0.38), UPS: 110.01 (+0.49)
Look for Shares of Amgen to Potentially Pullback after Yesterday's 1.30% Rise
Comtex SmarTrend(R) - Wed Jul 06, 12:19PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $152.95 to a high of $156.82. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $154.95 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 160.18 (-0.92)
Amgen Set to Possibly Pullback After Yesterday's Rally of 1.30%
Comtex SmarTrend(R) - Wed Jul 06, 12:17PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $152.95 to a high of $156.82. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $154.95 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 160.18 (-0.92)
Amgen's Kyprolis Gains Approval in EU for Label Expansion
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:37AM CDT
Amgen's (AMGN) Kyprolis label has been expanded in the EU for the treatment of relapsed multiple myeloma patients.
AMGN: 160.18 (-0.92), ABBV: 64.35 (+0.19), BMY: 75.39 (+0.11), CELG: 103.41 (-1.62)
Should Davita's (DVA) Stock Be in Your Portfolio Now?
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 8:40AM CDT
On Jul 5, 2016, we issued an updated research report on DaVita HealthCare Partners Inc. (DVA).
PMC: 25.91 (+0.27), DVA: 78.44 (+0.37), LHCG: 45.89 (+0.36), AMGN: 160.18 (-0.92)
AstraZeneca Skin Drug, Tralokinumab, Rights Licensed to LEO
Arpita Dutt - Zacks Investment Research - Wed Jul 06, 8:39AM CDT
AstraZeneca (AZN) out-licensed global rights to tralokinumab for skin diseases to LEO Pharma.
AGN: 238.28 (-2.31), VRX: 23.09 (-0.16), AZN: 29.97 (-0.14), AMGN: 160.18 (-0.92)
5 Dividend Growth Stocks to Excel in Any Market Condition
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 7:20AM CDT
With uncertainty ruling the markets since the beginning of the year, it's not surprising that dividend investing has emerged as one of the most popular investing themes.
HD: 135.15 (+0.81), WMT: 74.06 (+0.22), AMGN: 160.18 (-0.92), INTC: 34.38 (+0.38), UPS: 110.01 (+0.49)
European Commission Approves Extended Indication For Amgen's Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
PR Newswire - Mon Jul 04, 12:00AM CDT
Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.
AMGN: 160.18 (-0.92)
Xencor Stock Up On Cancer Drugs Partnership with Novartis
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 5:20PM CDT
Shares of Xencor, Inc. (XNCR) rallied 32.06% after the company announced that it has entered into a collaboration and license agreement with Novartis AG (NVS).
PFE: 36.15 (+0.03), AMGN: 160.18 (-0.92), XNCR: 17.93 (-0.69), NVS: 82.31 (+0.18)
Top 6 Research Reports for June 29, 2016
Sheraz Mian - Zacks Investment Research - Wed Jun 29, 1:35PM CDT
Top 6 Research Reports for June 29, 2016
BCS: 7.67 (+0.35), GILD: 86.25 (-0.30), EXPE: 111.28 (+1.85), KHC: 89.84 (-0.01), AMGN: 160.18 (-0.92), UPS: 110.01 (+0.49)
SmarTrend Watching for Potential Pullback in Shares of Amgen After 1.13% Gain
Comtex SmarTrend(R) - Wed Jun 29, 1:00PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $148.63 to a high of $150.27. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $149.30 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 160.18 (-0.92)
After Yesterday's Rally of 1.13% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 29, 12:58PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $148.63 to a high of $150.27. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $149.30 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 160.18 (-0.92)
Pfizer's PCSK9 Inhibitor Tops Two Additional Phase III Studies
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 10:09AM CDT
Pfizer's (PFE) bococizumab met the primary endpoints in two phase III studies in patients at high and very high risk for cardiovascular events.
PFE: 36.15 (+0.03), AMGN: 160.18 (-0.92), SNY: 41.42 (+0.57), REGN: 375.74 (-2.61)
Learn how to target an 20% return on Chipotle Mexican Grill, or get option-trade ideas on Amgen, Celgene, Google Inc., and SolarEdge Technologies or any stock you choose
PR Newswire - Thu Jun 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, CELG, CMG, GOOG, and SEDG.
SEDG: 19.82 (+0.14), CMG: 403.18 (+3.47), AMGN: 160.18 (-0.92), GOOGL: 727.20 (+9.42), GOOG: 715.09 (+9.46), CELGZ: 1.40 (-0.03), CELG: 103.41 (-1.62)
Achromatopsia - Pipeline Review, H1 2016 Featuring Amgen & Applied Genetic Technologies Corporation - Research and Markets
BusinessWire - Thu Jun 23, 6:42AM CDT
Research and Markets has announced the addition of the "Achromatopsia - Pipeline Review, H1 2016" report to their offering.
AMGN: 160.18 (-0.92)
Amgen Sponsors QB3@953 Incubator For Life Science Startups
PR Newswire - Wed Jun 22, 5:00PM CDT
Amgen (NASDAQ:AMGN) today announced a five-year, platinum sponsorship of the QB3@953 life sciences incubator to accelerate the development of new therapies to improve human health. The shared laboratory space at QB3@953 was created to help high-potential life science and biotech startups overcome a key obstacle for many early stage organizations - access to laboratory infrastructure.
AMGN: 160.18 (-0.92)
Global Epithelial Ovarian Cancer Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: bbVie, Amgen, Sotio - Research and Markets
BusinessWire - Wed Jun 22, 10:35AM CDT
Research and Markets has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2016" drug pipelines to their offering.
AMGN: 160.18 (-0.92)
Stock Market News for June 22, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:10AM CDT
Benchmarks ended slightly higher on Tuesday as the latest Brexit polls tilted slightly in favor of the ‘remain’ camp
JNJ: 122.93 (+0.08), MU: 12.64 (+0.02), PXD: 153.00 (-0.72), GILD: 86.25 (-0.30), EOG: 82.90 (+0.36), AMGN: 160.18 (-0.92), ABBV: 64.35 (+0.19), GOOGL: 727.20 (+9.42), CVX: 105.39 (+0.62), MSFT: 52.59 (+0.29)
Amgen Falls 1.08% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 21, 12:24PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $148.50 to a high of $151.47. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $149.55 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 160.18 (-0.92)
Amgen Humira Biosimilar Briefing Documents Look Good
Arpita Dutt - Zacks Investment Research - Mon Jul 11, 7:04AM CDT
An FDA advisory panel will be meeting tomorrow to review Amgen Inc.'s (AMGN) ABP 501, a biosimilar version of AbbVie's Humira.
INVA: 11.77 (+0.13), FCSC: 1.18 (-0.02), AMGN: 160.18 (-0.92), ABBV: 64.35 (+0.19)
Zacks.com featured highlights: Wal-Mart Stores, Home Depot, Amgen, United Parcel Service and Intel
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:30AM CDT
Zacks.com featured highlights: Wal-Mart Stores, Home Depot, Amgen, United Parcel Service and Intel
HD: 135.15 (+0.81), AMGN: 160.18 (-0.92), WMT: 74.06 (+0.22), INTC: 34.38 (+0.38), UPS: 110.01 (+0.49)
Look for Shares of Amgen to Potentially Pullback after Yesterday's 1.30% Rise
Comtex SmarTrend(R) - Wed Jul 06, 12:19PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $152.95 to a high of $156.82. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $154.95 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 160.18 (-0.92)
Amgen Set to Possibly Pullback After Yesterday's Rally of 1.30%
Comtex SmarTrend(R) - Wed Jul 06, 12:17PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $152.95 to a high of $156.82. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $154.95 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 160.18 (-0.92)
Amgen's Kyprolis Gains Approval in EU for Label Expansion
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:37AM CDT
Amgen's (AMGN) Kyprolis label has been expanded in the EU for the treatment of relapsed multiple myeloma patients.
AMGN: 160.18 (-0.92), ABBV: 64.35 (+0.19), BMY: 75.39 (+0.11), CELG: 103.41 (-1.62)
Should Davita's (DVA) Stock Be in Your Portfolio Now?
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 8:40AM CDT
On Jul 5, 2016, we issued an updated research report on DaVita HealthCare Partners Inc. (DVA).
PMC: 25.91 (+0.27), DVA: 78.44 (+0.37), LHCG: 45.89 (+0.36), AMGN: 160.18 (-0.92)
AstraZeneca Skin Drug, Tralokinumab, Rights Licensed to LEO
Arpita Dutt - Zacks Investment Research - Wed Jul 06, 8:39AM CDT
AstraZeneca (AZN) out-licensed global rights to tralokinumab for skin diseases to LEO Pharma.
AGN: 238.28 (-2.31), VRX: 23.09 (-0.16), AZN: 29.97 (-0.14), AMGN: 160.18 (-0.92)
5 Dividend Growth Stocks to Excel in Any Market Condition
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 7:20AM CDT
With uncertainty ruling the markets since the beginning of the year, it's not surprising that dividend investing has emerged as one of the most popular investing themes.
HD: 135.15 (+0.81), WMT: 74.06 (+0.22), AMGN: 160.18 (-0.92), INTC: 34.38 (+0.38), UPS: 110.01 (+0.49)
European Commission Approves Extended Indication For Amgen's Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
PR Newswire - Mon Jul 04, 12:00AM CDT
Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.
AMGN: 160.18 (-0.92)
Xencor Stock Up On Cancer Drugs Partnership with Novartis
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 5:20PM CDT
Shares of Xencor, Inc. (XNCR) rallied 32.06% after the company announced that it has entered into a collaboration and license agreement with Novartis AG (NVS).
PFE: 36.15 (+0.03), AMGN: 160.18 (-0.92), XNCR: 17.93 (-0.69), NVS: 82.31 (+0.18)
Top 6 Research Reports for June 29, 2016
Sheraz Mian - Zacks Investment Research - Wed Jun 29, 1:35PM CDT
Top 6 Research Reports for June 29, 2016
BCS: 7.67 (+0.35), GILD: 86.25 (-0.30), EXPE: 111.28 (+1.85), KHC: 89.84 (-0.01), AMGN: 160.18 (-0.92), UPS: 110.01 (+0.49)
SmarTrend Watching for Potential Pullback in Shares of Amgen After 1.13% Gain
Comtex SmarTrend(R) - Wed Jun 29, 1:00PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $148.63 to a high of $150.27. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $149.30 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 160.18 (-0.92)
After Yesterday's Rally of 1.13% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 29, 12:58PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $148.63 to a high of $150.27. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $149.30 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 160.18 (-0.92)
Pfizer's PCSK9 Inhibitor Tops Two Additional Phase III Studies
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 10:09AM CDT
Pfizer's (PFE) bococizumab met the primary endpoints in two phase III studies in patients at high and very high risk for cardiovascular events.
PFE: 36.15 (+0.03), AMGN: 160.18 (-0.92), SNY: 41.42 (+0.57), REGN: 375.74 (-2.61)
Learn how to target an 20% return on Chipotle Mexican Grill, or get option-trade ideas on Amgen, Celgene, Google Inc., and SolarEdge Technologies or any stock you choose
PR Newswire - Thu Jun 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, CELG, CMG, GOOG, and SEDG.
SEDG: 19.82 (+0.14), CMG: 403.18 (+3.47), AMGN: 160.18 (-0.92), GOOGL: 727.20 (+9.42), GOOG: 715.09 (+9.46), CELGZ: 1.40 (-0.03), CELG: 103.41 (-1.62)
Achromatopsia - Pipeline Review, H1 2016 Featuring Amgen & Applied Genetic Technologies Corporation - Research and Markets
BusinessWire - Thu Jun 23, 6:42AM CDT
Research and Markets has announced the addition of the "Achromatopsia - Pipeline Review, H1 2016" report to their offering.
AMGN: 160.18 (-0.92)
Amgen Sponsors QB3@953 Incubator For Life Science Startups
PR Newswire - Wed Jun 22, 5:00PM CDT
Amgen (NASDAQ:AMGN) today announced a five-year, platinum sponsorship of the QB3@953 life sciences incubator to accelerate the development of new therapies to improve human health. The shared laboratory space at QB3@953 was created to help high-potential life science and biotech startups overcome a key obstacle for many early stage organizations - access to laboratory infrastructure.
AMGN: 160.18 (-0.92)
Global Epithelial Ovarian Cancer Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: bbVie, Amgen, Sotio - Research and Markets
BusinessWire - Wed Jun 22, 10:35AM CDT
Research and Markets has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2016" drug pipelines to their offering.
AMGN: 160.18 (-0.92)
Stock Market News for June 22, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:10AM CDT
Benchmarks ended slightly higher on Tuesday as the latest Brexit polls tilted slightly in favor of the ‘remain’ camp
JNJ: 122.93 (+0.08), MU: 12.64 (+0.02), PXD: 153.00 (-0.72), GILD: 86.25 (-0.30), EOG: 82.90 (+0.36), AMGN: 160.18 (-0.92), ABBV: 64.35 (+0.19), GOOGL: 727.20 (+9.42), CVX: 105.39 (+0.62), MSFT: 52.59 (+0.29)
Amgen Falls 1.08% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 21, 12:24PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $148.50 to a high of $151.47. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $149.55 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 160.18 (-0.92)
